Gracell Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary

Gracell Biotechnologies

17/05/2021 15:26

* Gracell Biotechnologies Inc  GRCL.OQ  reported a quarterly
adjusted loss of 25 cents​​ per share for the quarter ended
in March. The mean expectation of four analysts for the quarter
was for a loss of 21 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Gracell Biotechnologies Inc's reported EPS for the quarter was
a loss of 25 cents​.
* The mean earnings estimate of analysts had fallen by
about 47.5% in the last three months.​ 
* In the last 30 days there have been no negative revisions of
earnings estimates 
* Gracell Biotechnologies Inc shares had fallen by 28.2% this
quarter.
* The company reported a quarterly loss of $15.21 million.
* Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $34.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated May 17 at 02:26 p.m. GMT.
​All figures in US dollars